Sas G, Owens R E, Smith J K, Middleton S, Cash J D
Br J Haematol. 1975 Sep;31(1):25-35. doi: 10.1111/j.1365-2141.1975.tb00828.x.
A series of in vitro studies designed to ascertain the potential in vivo thrombogenicity of human factor IX-containing concentrates is described. Using concentrates obtained from several different Centres the fibrinogen clotting time with some preparations was less than 6 h and/or the recalcification time of normal plasma was shortened. In some preparations, however, the plasma recalcification time was lengthened. Further studies revealed that all diluted factor-IX concentrates generated thrombin after recalcification, and that the rate of thrombin generation appeared to be characteristic of a particular preparation. This characteristic has been designated the TGt50, which is the incubation period in minutes, after recalcification, required to obtain a 50 s clotting time of a fibrinogen substrate. The TGt50 was found to correlate most strongly with recalcification time of celite exhausted plasma (P less than 0.001), but no correlation was observed between it and the immunological antithrombin III or factor-VIII antigen levels. Evidence is presented which suggests that the thrombin generation test and recalcification time of celite exhausted plasma may represent suitable in vitro quality control assays for factor-IX concentrates.
本文描述了一系列旨在确定含人凝血因子IX浓缩物体内潜在血栓形成性的体外研究。使用从几个不同中心获得的浓缩物,某些制剂的纤维蛋白原凝血时间小于6小时和/或正常血浆的复钙时间缩短。然而,在某些制剂中,血浆复钙时间延长。进一步研究表明,所有稀释的凝血因子IX浓缩物在复钙后均产生凝血酶,且凝血酶生成速率似乎是特定制剂的特征。这一特征被称为TGt50,即复钙后使纤维蛋白原底物达到50秒凝血时间所需的孵育时间(以分钟计)。发现TGt50与硅藻土耗尽血浆的复钙时间相关性最强(P小于0.001),但未观察到它与免疫抗凝血酶III或因子VIII抗原水平之间存在相关性。有证据表明,凝血酶生成试验和硅藻土耗尽血浆的复钙时间可能代表适用于凝血因子IX浓缩物的体外质量控制测定方法。